Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex

Science Translational Medicine

Volumn 4, Issue 162, 2012, Pages

  Foltz, Ian N ^a   Hu, Sylvia ^b   King, Chadwick ^a   Wu, Xinle ^b   Yang, Chaofeng ^c   Wang, Wei ^b   Weiszmann, Jennifer ^b   Stevens, Jennitte ^b   Chen, Jiyun Sunny ^b   Nuanmanee, Noi ^b   Gupte, Jamila ^b   Komorowski, Renee ^b   Sekirov, Laura ^a   Hager, Todd ^b   Arora, Taruna ^b   Ge, Hongfei ^b   Baribault, Helene ^b   Wang, Fen ^c   Sheng, Jackie ^b   Karow, Margaret ^b   Wang, Minghan ^b   Luo, Yongde ^c   McKeehan, Wallace ^c   Wang, Zhulun ^b   Véniant, Murielle M ^b   Li, Yang ^b   more..

^a Amgen British Columbia   (Canada)

^b AMGEN INC   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIOBESITY AGENT; BETA KLOTHO PROTEIN; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 21 MIMETIC MONOCLONAL ANTIBODY; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1C; GLUCOSE; INSULIN; KLOTHO PROTEIN; MONOCLONAL ANTIBODY; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HAPLORHINI; INSULIN BLOOD LEVEL; MOUSE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANIMALS; ANTIBODIES, MONOCLONAL; BODY WEIGHT; DIABETES MELLITUS; EPITOPES; FIBROBLAST GROWTH FACTORS; GLUCOSE; GLUCURONIDASE; HUMANS; MACACA FASCICULARIS; MICE; OBESITY; PHOSPHATES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 84870359606     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004690     Document Type: Article

References (39)

1. Y. C. Long, A. Kharitonenkov, Hormone-like fibroblast growth factors and metabolic regulation. Biochim. Biophys. Acta 1812, 791-795 (2011).
2. M. J. Potthoff, S. A. Kliewer, D. J. Mangelsdorf, Endocrine fibroblast growth factors 15/19 and 21: From feast to famine. Genes Dev. 26, 312-324 (2012).
3. A. Kharitonenkov, T. L. Shiyanova, A. Koester, A. M. Ford, R. Micanovic, E. J. Galbreath, G. E. Sandusky, L. J. Hammond, J. S. Moyers, R. A. Owens, J. Gromada, J. T. Brozinick, E. D. Hawkins, V. J. Wroblewski, D. S. Li, F. Mehrbod, S. R. Jaskunas, A. B. Shanafelt, FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627-1635 (2005).
4. T. Inagaki, P. Dutchak, G. Zhao, X. Ding, L. Gautron, V. Parameswara, Y. Li, R. Goetz, M. Mohammadi, V. Esser, J. K. Elmquist, R. D. Gerard, S. C. Burgess, R. E. Hammer, D. J.Mangelsdorf, S. A. Kliewer, Endocrine regulation of the fasting response by PPARa-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415-425 (2007).
5. M. K. Badman, A. Koester, J. S. Flier, A. Kharitonenkov, E. Maratos-Flier, Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150, 4931-4940 (2009).
6. Y. Ogawa, H. Kurosu, M. Yamamoto, A. Nandi, K. P. Rosenblatt, R. Goetz, A. V. Eliseenkova, M. Mohammadi, M. Kuro-o, bKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. U.S.A. 104, 7432-7437 (2007).
7. M. Suzuki, Y. Uehara, K. Motomura-Matsuzaka, J. Oki, Y. Koyama, M. Kimura, M. Asada, A. Komi-Kuramochi, S. Oka, T. Imamura, bKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22, 1006-1014 (2008).
8. H. Kurosu, M. Choi, Y. Ogawa, A. S. Dickson, R. Goetz, A. V. Eliseenkova, M. Mohammadi, K. P. Rosenblatt, S. A. Kliewer, M. Kuro-o, Tissue-specific expression of bKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687-26695 (2007).
9. X. Wu, H. Ge, B. Lemon, S. Vonderfecht, J. Weiszmann, R. Hecht, J. Gupte, T. Hager, Z. Wang, R. Lindberg, Y. Li, FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J. Biol. Chem. 285, 5165-5170 (2010).
10. K. Tomiyama, R. Maeda, I. Urakawa, Y. Yamazaki, T. Tanaka, S. Ito, Y. Nabeshima, T. Tomita, S. Odori, K. Hosoda, K. Nakao, A. Imura, Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc. Natl. Acad. Sci. U.S.A. 107, 1666-1671 (2010).
11. C. Yang, C. Jin, X. Li, F. Wang, W. L. McKeehan, Y. Luo, Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 7, e33870 (2012).
12. X. Wu, Y. Li, Therapeutic utilities of fibroblast growth factor 19. Expert Opin. Ther. Targets 15, 1307-1316 (2011).
13. S. Ito, S. Kinoshita, N. Shiraishi, S. Nakagawa, S. Sekine, T. Fujimori, Y. I. Nabeshima, Molecular cloning and expression analyses of mouse bklotho, which encodes a novel Klotho family protein. Mech. Dev. 98, 115-119 (2000).
14. K. Fon Tacer, A. L. Bookout, X. Ding, H. Kurosu, G. B. John, L. Wang, R. Goetz, M. Mohammadi, M. Kuro-o, D. J. Mangelsdorf, S. A. Kliewer, Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 24, 2050-2064 (2010).
15. A. L. Wu, G. Kolumam, S. Stawicki, Y. Chen, J. Li, J. Zavala-Solorio, K. Phamluong, B. Feng, L. Li, S. Marsters, L. Kates, N. van Bruggen, M. Leabman, A. Wong, D. West, H. Stern, E. Luis, H. S. Kim, D. Yansura, A. S. Peterson, E. Filvaroff, Y.Wu, J. Sonoda, Amelioration of type 2 diabetes by antibodymediated activation of fibroblast growth factor receptor 1. Sci. Transl. Med. 3, 113ra126 (2011).
16. S. Ussar, S. G. Vienberg, C. R. Kahn, Receptor antibodies as novel therapeutics for diabetes. Sci. Transl. Med. 3, 113ps47 (2011).
17. Y. Hayashi, N. Okino, Y. Kakuta, T. Shikanai,M. Tani, H. Narimatsu, M. Ito, Klotho-related protein is a novel cytosolic neutral b-glycosylceramidase. J. Biol. Chem. 282, 30889-30900 (2007).
18. M. M. Véniant, R. Komorowski, P. Chen, S. Stanislaus, K. Winters, T. Hager, L. Zhou, R. Wada, R. Hecht, J. Xu, Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153, 4192-4203 (2012).
19. J. Yie, R. Hecht, J. Patel, J. Stevens, W. Wang, N. Hawkins, S. Steavenson, S. Smith, D. Winters, S. Fisher, L. Cai, E. Belouski, C. Chen, M. L. Michaels, Y. S. Li, R. Lindberg, M. Wang, M. Véniant, J. Xu, FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett. 583, 19-24 (2009).
20. X. Wu, Y. Li, Understanding the structure-function relationship between FGF19 and its mitogenic and metabolic activities. Adv. Exp. Med. Biol. 728, 195-213 (2012).
21. J. Yie, W. Wang, L. Deng, L. T. Tam, J. Stevens, M. M. Chen, Y. Li, J. Xu, R. Lindberg, R. Hecht, M. Véniant, C. Chen, M. Wang, Understanding the physical interactions in the FGF21/FGFR/b-Klotho complex: Structural requirements and implications in FGF21 signaling. Chem. Biol. Drug Des. 79, 398-410 (2012).
22. J. Xu, D. J. Lloyd, C. Hale, S. Stanislaus, M. Chen, G. Sivits, S. Vonderfecht, R. Hecht, Y. S. Li, R. A. Lindberg, J. L. Chen, D. Y. Jung, Z. Zhang, H. J. Ko, J. K. Kim, M. M. Véniant, Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250-259 (2009).
23. T. Coskun, H. A. Bina, M. A. Schneider, J. D. Dunbar, C. C. Hu, Y. Chen, D. E. Moller, A. Kharitonenkov, Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149, 6018-6027 (2008).
24. A. Kharitonenkov, P. Larsen, FGF21 reloaded: Challenges of a rapidly growing field. Trends Endocrinol. Metab. 22, 81-86 (2011).
25. J. Gupte, L. Yang, X. Wu, J. Weiszmann, R. Hecht, B. Lemon, R. Lindberg, Z. Wang, Y. Li, The FGFR D3 domain determines receptor selectivity for fibroblast growth factor 21. J. Mol. Biol. 408, 491-502 (2011).
26. A. Kharitonenkov, J. D. Dunbar, H. A. Bina, S. Bright, J. S. Moyers, C. Zhang, L. Ding, R. Micanovic, S. F. Mehrbod, M. D. Knierman, J. E. Hale, T. Coskun, A. B. Shanafelt, FGF-21/FGF-21 receptor interaction and activation is determined by bKlotho. J. Cell. Physiol. 215, 1-7 (2008).
27. P. A. Dutchak, T. Katafuchi, A. L. Bookout, J. H. Choi, R. T. Yu, D. J. Mangelsdorf, S. A. Kliewer, Fibroblast growth factor-21 regulates PPAR g activity and the antidiabetic actions of thiazolidinediones. Cell 148, 556-567 (2012).
28. W. Wei, P. A. Dutchak, X. Wang, X. Ding, X. Wang, A. L. Bookout, R. Goetz, M. Mohammadi, R. D. Gerard, P. C. Dechow, D. J. Mangelsdorf, S. A. Kliewer, Y. Wan, Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor g. Proc. Natl. Acad. Sci. U.S.A. 109, 3143-3148 (2012).
29. W. Wente, A. M. Efanov, M. Brenner, A. Kharitonenkov, A. Köster, G. E. Sandusky, S. Sewing, I. Treinies, H. Zitzer, J. Gromada, Fibroblast growth factor-21 improves pancreatic b-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55, 2470-2478 (2006).
30. D. A. Sarruf, J. P. Thaler, G. J. Morton, J. German, J. D. Fischer, K. Ogimoto, M. W. Schwartz, Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59, 1817-1824 (2010).
31. B. K. Tan, M. Hallschmid, R. Adya, W. Kern, H. Lehnert, H. S. Randeva, Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: Relationship with plasma FGF21 and body adiposity. Diabetes 60, 2758-2762 (2011).
32. X. Ding, J. Boney-Montoya, B. M. Owen, A. L. Bookout, K. C. Coate, D. J. Mangelsdorf, S. A. Kliewer, bKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 16, 387-393 (2012).
33. M. M. Véniant, C. Hale, J. Helmering, M. M. Chen, S. Stanislaus, J. Busby, S. Vonderfecht, J. Xu, D. J. Lloyd, FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One 7, e40164 (2012).
34. A. A. Shukla, B. Hubbard, T. Tressel, S. Guhan, D. Low, Downstreamprocessing ofmonoclonal antibodies-Application of platform approaches. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 848, 28-39 (2007).
35. L. L. Green, M. C. Hardy, C. E. Maynard-Currie, H. Tsuda, D. M. Louie,M. J. Mendez, H. Abderrahim, M. Noguchi, D. H. Smith, Y. Zeng, N. E. David, H. Sasai, D. Garza, D. G. Brenner, J. F. Hales, R. P. McGuinness, D. J. Capon, S. Klapholz, A. Jakobovits, Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. 7, 13-21 (1994).
36. M. J. Mendez, L. L. Green, J. R. Corvalan, X. C. Jia, C. E. Maynard-Currie, X. D. Yang, M. L. Gallo, D. M. Louie, D. V. Lee, K. L. Erickson, J. Luna, C. M. Roy, H. Abderrahim, F. Kirschenbaum, M. Noguchi, D. H. Smith, A. Fukushima, J. F. Hales, S. Klapholz, M. H. Finer, C. G. Davis, K. M. Zsebo, A. Jakobovits, Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15, 146-156 (1997).
37. W. He, Y. Barak, A. Hevener, P. Olson, D. Liao, J. Le, M. Nelson, E. Ong, J. M. Olefsky, R. M. Evans, Adipose-specific peroxisome proliferator-activated receptor g knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U.S.A. 100, 15712-15717 (2003).
38. R. Trokovic, N. Trokovic, S. Hernesniemi, U. Pirvola, D. M. Vogt Weisenhorn, J. Rossant, A. P. McMahon, W. Wurst, J. Partanen, FGFR1 is independently required in both developing mid- and hindbrain for sustained response to isthmic signals. EMBO J. 22, 1811-1823 (2003).
39. C. Yang, C. Wang, M. Ye, C. Jin, W. He, F. Wang, W. L. McKeehan, Y. Luo, Control of lipid metabolism by adipocyte FGFR1-mediated adipohepatic communication during hepatic stress. Nutr. Metab. 9, 94 (2012).